Gastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight According to DelveInsight’s analysis, the market for ...

Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

Medically reviewed by Marla Anderson, MD Stomach cancer—or gastric cancer—occurs when cells in the lining of the stomach wall mutate and grow uncontrollably. The stomach wall has five layers, and ...

Cogent Biosciences, Inc. topline results for phase 2/3 studies on bezuclastinib targeting systemic mastocytosis & GIST are ...

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates-only 10% after five years.

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

which is already approved by the United States Food and Drug Administration to treat gastrointestinal stromal tumors ... Genetic Mutations Linked to Toxin Exposure Found in Firefighters' Brain ...

Hoth Therapeutics Inc. has released preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST). HT-KIT yields significantly reduced ...